Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.88 USD
Change Today +0.69 / 7.51%
Volume 19.9K
MCUR On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 4:00 PM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

macrocure ltd (MCUR) Snapshot

Open
$9.65
Previous Close
$9.19
Day High
$9.90
Day Low
$9.11
52 Week High
02/12/15 - $14.30
52 Week Low
10/1/14 - $6.82
Market Cap
159.8M
Average Volume 10 Days
26.7K
EPS TTM
$-2.17
Shares Outstanding
16.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MACROCURE LTD (MCUR)

macrocure ltd (MCUR) Related Businessweek News

No Related Businessweek News Found

macrocure ltd (MCUR) Details

Macrocure Ltd., a biotechnology company, focuses on developing, manufacturing, and commercializing novel cell therapy products for the treatment of chronic and other hard-to-heal wounds in Israel. Its lead cell-based biological product includes CureXcell, which is in two Phase III clinical trials for the treatment of hard-to-heal diabetic foot ulcers and hard-to-heal venous leg ulcers. Macrocure Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.

28 Employees
Last Reported Date: 03/18/15
Founded in 2008

macrocure ltd (MCUR) Top Compensated Officers

President and Chief Executive Officer
Total Annual Compensation: $1.2M
Chief Medical Officer
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2014.

macrocure ltd (MCUR) Key Developments

Macrocure Ltd. Reports Audited Consolidated Earnings Results Fourth Quarter and Full Year Period Ended December 31, 2014; Provides Cash Flow Guidance for 2015

Macrocure Ltd. reported audited consolidated earnings results fourth quarter and full year period ended December 31, 2014. For the fourth quarter, the company posted a net loss of $7.6 million, or $0.42 loss per basic and diluted share compared with a net loss of $3.9 million, or $0.52 loss per basic and diluted share, in the fourth quarter of 2013. Operating loss was $7,541,000 against $3,855,000 a year ago. Loss before income tax was $7,635,000 against $3,805,000 a year ago. Net cash used in operating activities was $5,649,000 against $3,796,000 a year ago. Purchase of property and equipment was $1,000 against $46,000 a year ago. For the twelve months, the company posted a net loss of $25.5 million, or $2.15 loss per basic and diluted share, compared with a net loss of $18.3 million, or $2.46 loss per basic and diluted share, for the comparable period in 2013. Operating loss was $20,916,000 against $13,870,000 a year ago. Loss before income tax was $25,420,000 against $18,175,000 a year ago. Net cash used in operating activities was $18,017,000 against $9,939,000 a year ago. Purchase of property and equipment was $227,000 against $116,000 a year ago. The company expects cash used for ongoing operating activities in 2015 will be in the range from $21 million to $25 million, reflecting anticipated expenditures to complete current phase III clinical trials in process 2015. This range excludes approximately $4 million in potential capital expenditures in 2015 primarily for new U.S. manufacturing facility; the exact timing of such capital expenditures is yet to be determined.

Macrocure Ltd. Appoints Ramesh Tharuvai as Vice President, Operations Effective March 2, 2015

Macrocure Ltd. announced that Dr. Ramesh Tharuvai has joined Macrocure as Vice President, Operations effective March 2, 2015. Most recently, Dr. Tharuvai was Vice President, Manufacturing and Product Supply, at Nuron Biotech, a private, clinical stage biopharmaceuticals company. Prior to Nuron, Dr. Tharuvai held senior-level positions at Pfizer and Wyeth within supply chain and operations. For more than 10 years, he was responsible for modeling, redesigning, and improving performance in several global product portfolios as well as establishing the Sales & Operations Planning process for Wyeth's Vaccine business and global portfolio. At Pfizer, Dr. Tharuvai had responsibility for the Specialty Care supply chain, which included 22 brands of biologics, vaccines, and small molecules.

Macrocure Ltd. to Report Q4, 2014 Results on Mar 17, 2015

Macrocure Ltd. announced that they will report Q4, 2014 results at 5:00 PM, Israel Standard Time on Mar 17, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MCUR:US $9.88 USD +0.69

MCUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MCUR.
View Industry Companies
 

Industry Analysis

MCUR

Industry Average

Valuation MCUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MACROCURE LTD, please visit www.macrocure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.